01

ABBVIE

U.S.A

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-11-09

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 9139536

Drug Substance Claim :

Drug Product Claim :

Application Number : 208624

Patent Use Code : U-1753

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2028-11-09

Product Web Link

Corporate PDF

02

ABBVIE

U.S.A

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-04-10

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 9044480

Drug Substance Claim :

Drug Product Claim :

Application Number : 208624

Patent Use Code : U-1638

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2031-04-10

Product Web Link

Corporate PDF

03

ABBVIE

U.S.A

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-09-04

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 8466159

Drug Substance Claim :

Drug Product Claim :

Application Number : 208624

Patent Use Code : U-1637

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2032-09-04

Product Web Link

Corporate PDF

04

ABBVIE

U.S.A

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-06-10

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 9006387

Drug Substance Claim :

Drug Product Claim :

Application Number : 208624

Patent Use Code : U-1687

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2030-06-10

Product Web Link

Corporate PDF

05

ABBVIE

U.S.A

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-09-17

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 8501238

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208624

Patent Use Code : U-1636

Patent Use Description : USE OF DASABUVIR TO IN...

Patent Expiration Date : 2028-09-17

Product Web Link

Corporate PDF

06

ABBVIE

U.S.A

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-09-10

OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 8642538

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 207931

Patent Use Code : U-1638

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2029-09-10

Product Web Link

Corporate PDF

07

ABBVIE

U.S.A

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-04-10

OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 9044480

Drug Substance Claim :

Drug Product Claim :

Application Number : 207931

Patent Use Code : U-1638

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2031-04-10

Product Web Link

Corporate PDF

08

ABBVIE

U.S.A

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-06-10

OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 9006387

Drug Substance Claim :

Drug Product Claim :

Application Number : 207931

Patent Use Code : U-1687

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2030-06-10

Product Web Link

Corporate PDF

09

ABBVIE

U.S.A

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2035-01-02

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 9333204

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208624

Patent Use Code : U-1889

Patent Use Description :

Patent Expiration Date : 2035-01-02

Product Web Link

Corporate PDF

10

ABBVIE

U.S.A

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-09-10

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 8642538

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208624

Patent Use Code : U-1638

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2029-09-10

Product Web Link

Corporate PDF

Information, Expiry & Status of FDA Orange Book Patents covering Ombitasvir

Ombitasvir

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers

2 Listed Suppliers

INTERMEDIATES

1 API Suppliers

FINISHED DOSAGE FORMULATIONS

2 FDF Dossiers

2 FDA Orange Book

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Seqens

1 PMC Isochem

1 Bioplus Life Sciences

EXCIPIENTS BY APPLICATIONS

2 Emulsifying Agents

1 Solubilizers

1 Topical

1 Surfactant & Foaming Agents

1 Thickeners and Stabilizers

1 Film Formers & Plasticizers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow

30 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 Annual Reports

PATENTS & EXCLUSIVITIES

31 US Patents

Filters

01

02

03

04

05

06

07

08

09

10

TABLET;ORAL - 12.5MG;75MG;50MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons